Citi lowered the firm’s price target on Coherus Biosciences to $11 from $14 and keeps a Buy rating on the shares. The analyst says that after a strong beat in Q2, Street expectations were “clearly overly-exuberant” for the Q3 print “which offered a stark reminder that predicting new biosimilar commercial launches is extremely tricky.” The firm reduced 2023 estimates to be in-line with guidance.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CHRS:
- Coherus Biosciences cut to Hold at Maxim on slow start for Yusimry
- Coherus Biosciences downgraded to Hold from Buy at Maxim
- Coherus Biosciences price target lowered to $12 from $20 at Truist
- Coherus Biosciences price target lowered to $13 from $20 at H.C. Wainwright
- Coherus Biosciences reports Q3 EPS (27c), consensus (31c)